Skip to main content

Table 7 Patients and tumor characteristics of the selected studies Melanoma and Target Therapy

From: Oligometastasis and local ablation in the era of systemic targeted and immunotherapy

a
Authors
(year of publication)
[reference]
N of pts underwent SBRTType of studyPrimary tumorN of mts underwent to SBRTType of Oligometases and organ involvedMedian total dose (dose per fractionBEDSystemic TherapyMts size (cm)
Kotecha 2017 [45]191 (19 pts. had BRAF mutated tumorsa)retrospectivemelanoma793 (81 received BRAFi)BrainAccording to the RTOG protocol 90–05 BRAFi1
Wolf 2016 [39]80 (31 received BRAFi)prospectivemelanoma Brain    
Franceschini 2017 [44]31 (3 received BRAFi)retrospectivemelanoma38Extracranial (lung, liver, nodes)48 Gy (4)>100Gy in 74% of ptsBRAFi39.6 cm3 (mean)
Ahmed 2016 [40]96 (18 received BRAFi, 12 received BRAF/ MEKi)retrospectivemelanoma314 (103 received Targeted Therapy)Brain24 Gy(1) BRAFi or BRAF/ MEKi0.1 cm3
Gaudy-Marqueste 2014 [41]30retrospectivemelanoma263BrainRange 20–28 Gy Vemurafenib (26) or Dabrafenib (4)N/A
Hecht 2018 [46]39retrospectivemelanoma Brain  Vemurafenib (23) or Dabrafenib (16) 
Ly 2015 [42]52 (17 received BRAFi)retrospectivemelanoma198 (96 received BRAFi)Brain20 Gy (1)   
Mastorakos 2018 [47]67retrospectivemelanoma Brain, extracranial mts.According to RTOG 95–08 guidelines_
19.2 Gy
  1.1 cm3
Patel 2017 [43]87 (15 received BRAFi)retrospectivemelanoma157 (32 received BRAFi)Brain21 Gy Vemurafenib (14) or Dabrafenib (1)0.12 cm3
b
Authors (Year of Publication)
[reference]
Local ControlProgression Free SurvivalOverall SurvivalToxicity
Kotecha 2017 [45]N.S.N.S.N.S.N.S.
Wolf 2016 [39]94.6%3.9 mo13 mo (median)a
Actuarial:
83% at 3 mo
65% at 6 mo
46% at 12 mo
No increase in hemorrage rates in SRS + BRAFi
Franceschini 2017 [44]96.6% at 12 mo
82.8% at 24 mo
5.8 mo (median)
Actuarial:
48.2% at 6 mo
18.5% at 12 mo
13.9% at 24 mo
10.6 mo (median)
Actuarial:
77% at 6 mo
41% at 12 mo
21% at 24 mo
Acute
1 G2 (pneumonia)
Late
1 G2 pneumonia
1 G2 dyspnea
1 gastric ulceration
Ahmed 2016 [40]89% at 6 mo
83% at 12 mo
3.4 mo (median)
Actuarial(BRAF/MEKi)
58% at 6 mo
39% 1 t 12 mo
Actuarial (BRAFi)
29% at 6 mo
12% at 12 mo
Actuarial (BRAF/MEKi)
83% at 6 mo
75% at 12 mo
Actuarial (BRAFi)
71% at 6 mo
29% at 12 mo
1 G2 headache
1 radionecrosis
Gaudy-Marqueste 2014 [41]  24.8 weeks (median)20% of pts. presented neurological symptoms
Hecht 2018 [46]No difference in median values between Concomitant and Interrupted treatmentConcomitant BRAFi: 4.2 mo
Interrupted BRAFi:
5.8 mo
Concomitant BRAFi: 7.3 mo
Interrupted BRAFi: 9.8 mo
Radiation dermatits > G1:
Concomitant BRAFI: 35% of pts.
Interrupted BRAFi: 14%.
Ly 2015 [42]85% at 1 yr32.3% at 1 yr50.2% at 1 yrFreedom from intratumoral hemmorrhage at 1 year: 39.3%
Mastorakos 2018 [47]23% local progression rate at 1 yr 13 mo (median)
Actuarial:
70.1% at 6 mo
52.2% at 12 mo
20.9% at 24 mo
10.4% of pts. with Inttracranial hemmorhage
Patel 2017 [43]3.3% LR at 1 yrN.S.78.6% at 6 mo
64.3% at 12 mo
8 pts. developed symptomatic RN
  1. afrom date of diagnosis of BM